AstraZeneca: to fully acquire Caelum Biosciences
(CercleFinance.com) - AstraZeneca will acquire all remaining shares in Caelum Biosciences for CAEL-101, a potentially first-in-class fibril-reactive monoclonal antibody (mAb) for the treatment of light chain amyloidosis (AL).
"AL amyloidosis is a rare disease in which misfolded amyloid proteins build up in organs throughout the body, including the heart and kidneys, causing significant organ damage and failure that may ultimately be fatal," the group said.
CAEL-101 is currently being evaluated in the Cardiac Amyloid Reaching for Extended Survival (CARES) Phase III clinical program, in combination with standard of care (SoC), in AL amyloidosis.
Copyright (c) 2021 CercleFinance.com. All rights reserved.
"AL amyloidosis is a rare disease in which misfolded amyloid proteins build up in organs throughout the body, including the heart and kidneys, causing significant organ damage and failure that may ultimately be fatal," the group said.
CAEL-101 is currently being evaluated in the Cardiac Amyloid Reaching for Extended Survival (CARES) Phase III clinical program, in combination with standard of care (SoC), in AL amyloidosis.
Copyright (c) 2021 CercleFinance.com. All rights reserved.